Acquiring Company
BioNTech
Acquired Company
Biotheus
Mainz
ZhuhaiBiotechnologyHealth CareTherapeuticsBiopharmaBiotechnologyHealth CareMedicalTherapeuticsDescription
BioNTech SE has successfully completed the acquisition of Biotheus, a clinical-stage biotechnology company based in China. This acquisition reinforces BioNTech's commitment to advancing its oncology strategy, enhancing the company's capabilities in researching, developing, and commercializing innovative pan-tumor technology platforms for the treatment of advanced cancers. The strategic acquisition also establishes Biotheus as a new indirect Chinese subsidiary of BioNTech, providing access to local research and development resources, and an advanced biologics manufacturing facility.
Quick answer
BioNTech is acquiring Biotheus, announced February 4, 2025. BioNTech is based in Mainz, Rhineland Palatinate, Germany.
- How much did BioNTech pay for Biotheus?
- The deal value was not disclosed.
- What does BioNTech do?
- BioNTech is a biopharmaceutical company dedicated to harnessing the power of the immune system to develop innovative cancer therapies and treatments for other serious diseases.
- Where are BioNTech and Biotheus based?
- BioNTech is based in Mainz, Rhineland Palatinate, Germany. Biotheus is based in Zhuhai, Guangdong, China.
- Who are the decision-makers at BioNTech?
- Fundz holds 1 contact at BioNTech. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Other recent acquisitions in Therapeutics and Biopharma
Deals where the buyer or target shares a sector with this one, within 45 days, from Fundz verified event records.
- Flourish Research acquires Diablo Clinical Research to expand therapeutic coverage (February 18, 2025)
- AbbVie completes acquisition of Nimble Therapeutics to expand its immunology pipeline (January 23, 2025)
- Exicure, Inc. completes acquisition of GPCR Therapeutics USA Inc. to enhance its pipeline for cell and gene therapies (January 22, 2025)
- Vivo Infusion completes acquisition of Neurology Institute of San Antonio and Vista Infusions to expand infusion services (January 9, 2025)
- START acquires Carolina Urologic Research Center (March 18, 2025)
- Gleamer acquires Pixyl and Caerus Medical (March 11, 2025)
Who to call at BioNTech, and when
When BioNTech changes hands, the new owners review vendors, systems and leadership. That is when the door opens.
- An alert the day BioNTech raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at BioNTech, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at BioNTech. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment BioNTech makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Frequently asked
Who acquired Biotheus?
Biotheus was acquired by BioNTech, based in Mainz. The deal was reported on February 4, 2025. BioNTech is a biopharmaceutical company dedicated to harnessing the power of the immune system to develop innovative cancer therapies and treatments for other serious diseases. BioNTech is publicly traded (BNTX) and operates in Biotechnology.
When did BioNTech acquire Biotheus?
BioNTech's acquisition of Biotheus was reported on February 4, 2025. BioNTech SE has successfully completed the acquisition of Biotheus, a clinical-stage biotechnology company based in China. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does Biotheus do?
Biotheus is a clinical-stage biotechnology company dedicated to the discovery and development of novel antibodies to address unmet medical needs of patients with oncological or inflammatory diseases. It is privately held, operating in Biotechnology, and is based in Zhuhai.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.